ArticleRheumatology (Oxford, England)2023
Dilemma of immunosuppression and infection risk in systemic lupus erythematosus.
Article in Rheumatology (Oxford, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Risk factors for acute kidney injury in Chinese patients with lupus nephritis: a meta-analysis.BMC nephrology · 2026Pooled it
- Vaccination and the risk of systemic lupus erythematosus: a meta-analysis of observational studies.Arthritis research & therapy · 2024Pooled it
- Efficacy and safety of anifrolumab in patients with systemic lupus erythematosus without prior immunosuppressant use: post hoc analysis of phase 3 TULIP-1 and TULIP-2 trials.Lupus science & medicine · 2026Trial
- Large language models in the diagnosis and treatment of immunosuppression-related infections in rheumatic diseases: a comparative, vignette-based study.Rheumatology international · 2026Article
- Obeticholic acid alleviates lupus pathology by inhibiting T follicular helper cell differentiation.EMBO molecular medicine · 2026Article
- Rare Pediatric Male Presentation of Systemic Lupus Erythematosus With Catastrophic Antiphospholipid Syndrome Following Pulmonary Tuberculosis: A Case Report.Clinical case reports · 2026Article
- Real-world experience with personalised belimumab spacing in sustained SLE remission: a multicentre study.Lupus science & medicine · 2026Article
- Viral metagenomic analysis of the blood virome in patients with multiple autoimmune diseases.Virology journal · 2026Article
- Intersection Between Systemic Autoimmune Diseases, Primary Immunodeficiency and Cancer: a Field in its Infancy.Journal of clinical immunology · 2026Review
- Corticosteroids in immunocompromised ICU patients with pneumonia: risks, evidence, and clinical practice.Pneumonia (Nathan Qld.) · 2026Review
- Incidence and disease burden of bronchiectasis in systemic lupus erythematosus: a nationwide population-based study in Korea.RMD open · 2026Article
- Low-dose IL-2 therapy for immune-related adverse events via Tfh/Treg balance modulation: a prospective cohort and murine model study.Cancer immunology, immunotherapy : CII · 2026Article
- Localized NF-κB Inhibition Reduces Lipid Nanoparticle-Associated Inflammation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Jieduquyuziyin prescription for systemic lupus erythematosus: a system-level therapeutic strategy for immunological recalibration.Chinese medicine · 2026Review
- Article
- Targeting STAT3 in systemic lupus erythematosus and lupus nephritis: mechanisms, therapeutic advances, and structure-informed perspectives.Frontiers in pharmacology · 2026Review
- Sepsis in Autoimmune Rheumatic Diseases: Risk Factors, Pathophysiology, and Outcomes.Risk management and healthcare policy · 2026Review
- Accelerated immunosenescence in SLE: current evidence and clinical translation.Frontiers in immunology · 2026Review
- Beyond the trial: a single-center retrospective review of real-world lupus nephritis management and outcomes.Frontiers in medicine · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with SLE are at high risk of various infections as evidenced by a number of studies. The main determinants of infection in SLE are disease activity, organ damage, and often inevitable medication. The molecular and cellular mechanisms underlying infection remain unclear. Impaired immunity, immunosuppressants and corticosteroids clearly increase the risk of infection, whereas some medications, such as low-dose IL-2, hydroxychloroquine and IVIG are safe in SLE patients with substantial evidence. It is important to balance the immunosuppression and infection risks in practice. This article focuses on medication-related infections in SLE and discusses the therapeutic options for the disease in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.